Brief: 60 Degrees Pharmaceuticals To Sponsor Pre-Clinical Studies Of Tafenoquine Use In Candida Spp, Including Candida Auris
20/02/2024 13:03
Feb 20 (Reuters) - 60 Degrees Pharmaceuticals Inc
SXTP.O :
* 60 DEGREES PHARMACEUTICALS TO SPONSOR PRE-CLINICAL STUDIES
OF
TAFENOQUINE USE IN CANDIDA SPP, INCLUDING CANDIDA AURIS
* 60 DEGREES PHARMACEUTICALS INC: MONASH UNIVERSITY WILL
CONDUCT
STUDIES BEGINNING IN Q2 OF 2024
Source text for Eikon: ID:nGNX7R0ZdB
Further company coverage: SXTP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM